A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
Public ClinicalTrials.gov record NCT07355218. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-Blind,Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants With Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care (ELOWEN-2)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic disease. Study details include: Study Duration: Up to 35 weeks. Treatment Duration: 24 weeks. Visit Frequency: every 4 weeks, with the exception of the Week 2 televisit. Study Intervention Name: Enpatoran, Placebo. Intervention Form: Film-coated tablet.
Study identification
- NCT ID
- NCT07355218
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 202 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2026
- Primary completion
- May 24, 2029
- Completion
- May 24, 2029
- Last update posted
- Aug 16, 2026
2026 – 2029
United States locations
- U.S. sites
- 13
- U.S. states
- 7
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Inland Rheumatology Clinical Trials, Inc. | Upland | California | 91786 | Recruiting |
| Omega Research Debary, LLC | DeBary | Florida | 32713 | Recruiting |
| South Florida Rheumatology | Hollywood | Florida | 33026 | Recruiting |
| GTL Medical And Research Group | Miami | Florida | 33173 | Recruiting |
| Bolanos Clinical Research | Pembroke Pines | Florida | 33026 | Recruiting |
| Vantage Clinical Trials | Tampa | Florida | 33603 | Recruiting |
| Dawes Fretzin Clinical Research Group, LLC | Indianapolis | Indiana | 46250 | Recruiting |
| Accurate Clinical Research Inc. - Lake Charles | Lake Charles | Louisiana | 70605 | Recruiting |
| Oakland Hills Dermatology | Auburn Hills | Michigan | 48326 | Recruiting |
| Arthritis and Osteoporosis Consultants of the Carolinas II, LLC | Charlotte | North Carolina | 28207 | Recruiting |
| Superior Clinical Research, LLC | Smithfield | North Carolina | 27577 | Recruiting |
| North Texas Center for Clinical Research | Frisco | Texas | 75034 | Recruiting |
| Accurate Clinical Research | Humble | Texas | 77346 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07355218, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 16, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07355218 live on ClinicalTrials.gov.